Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study
Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Design

**Study Design: SINGLE**

- **Background:** Randomized, double-blind study, phase 3 trial comparing dolutegravir + abacavir-lamivudine with efavirenz-tenofovir DF-emtricitabine
- **Inclusion Criteria (n = 833)**
  - Antiretroviral-naïve patients
  - Age ≥ 18
  - HIV RNA ≥ 1,000 copies/mL
  - No active CDC AIDS condition
- **Treatment Arms**
  - Dolutegravir (QD) + Abacavir-lamivudine
  - Efavirenz-Tenofovir-Emtricitabine

Dolutegravir + ABC-3TC (n = 414)

Efavirenz-TDF-FTC (n = 419)

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Result

Week 48 Virologic Response (ITT Analysis)

<table>
<thead>
<tr>
<th>Baseline HIV RNA</th>
<th>Dolutegravir + Abacavir-Lamivudine</th>
<th>Efavirenz-Tenofovir DF-Emtricitabine</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>88/414</td>
<td>81/419</td>
</tr>
<tr>
<td>≤ 100,000 copies/mL</td>
<td>253/280</td>
<td>238/288</td>
</tr>
<tr>
<td>&gt; 100,000 copies/mL</td>
<td>111/134</td>
<td>100/131</td>
</tr>
</tbody>
</table>

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Result

Week 48 Virologic Response (ITT Analysis)

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Result

Mean Change from Baseline in Serum Creatinine Levels

© 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Conclusions: “Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine.”
The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.